Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Mereo BioPharma regains compliance with Nasdaq minimum bid price requirement » 16:06
07/05/22
07/05
16:06
07/05/22
16:06
MREO

Mereo BioPharma

$1.40 /

+0.015 (+1.08%)

Mereo BioPharma announced…

Mereo BioPharma announced that it has received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450a, the "Minimum Bid Price Requirement, and the matter is closed. As announced on May 26 the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company's American Depositary Shares had been below US$1.00 for 30 consecutive business days. To regain compliance with the Minimum Bid Price Requirement, Mereo was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The Notification Letter confirmed that the Company evidenced a closing bid price of the Company's ADSs on Nasdaq at or greater than the $1.00 per ADS minimum requirement for the last 10 consecutive business days from June 17 to July 1 and that the Company has regained compliance with Minimum Bid Price Requirement.

ShowHide Related Items >><<
MREO Mereo BioPharma
$1.40 /

+0.015 (+1.08%)

MREO Mereo BioPharma
$1.40 /

+0.015 (+1.08%)

06/06/22 Needham
Mereo BioPharma price target lowered to $5 from $10 at Needham
MREO Mereo BioPharma
$1.40 /

+0.015 (+1.08%)

Over a week ago
Periodicals
AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports » 06:28
06/17/22
06/17
06:28
06/17/22
06:28
MREO

Mereo BioPharma

/

+

, AZN

AstraZeneca

$60.83 /

+0.28 (+0.46%)

AstraZeneca (AZN) is…

AstraZeneca (AZN) is considering a bid for Mereo Biopharma (MREO), a specialist in cancer and rare diseases, the U.K. Times' Dominic Walsh reports. Reference Link

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

AZN AstraZeneca
$60.83 /

+0.28 (+0.46%)

MREO Mereo BioPharma
/

+

06/06/22 Needham
Mereo BioPharma price target lowered to $5 from $10 at Needham
AZN AstraZeneca
$60.83 /

+0.28 (+0.46%)

06/14/22 UBS
AstraZeneca downgraded to Neutral from Buy at UBS
05/24/22 Danske Bank
AstraZeneca initiated with a Buy at Danske Bank
05/18/22 Kepler Cheuvreux
AstraZeneca downgraded to Hold from Buy at Kepler Cheuvreux
04/21/22 Morgan Stanley
AstraZeneca price target raised to 11,100 GBp from 10,200 GBp at Morgan Stanley
AZN AstraZeneca
$60.83 /

+0.28 (+0.46%)

AZN AstraZeneca
$60.83 /

+0.28 (+0.46%)

AZN AstraZeneca
$60.83 /

+0.28 (+0.46%)

AZN AstraZeneca
$60.83 /

+0.28 (+0.46%)

Recommendations
Mereo BioPharma price target lowered to $5 from $10 at Needham » 08:24
06/06/22
06/06
08:24
06/06/22
08:24
MREO

Mereo BioPharma

/

+

Needham analyst Chad…

Needham analyst Chad Messer lowered the firm's price target on Mereo BioPharma (MREO) to $5 from $10 after the company reported "incremental" progress for Etigilimab at ASCO but keeps a Buy rating on the shares. The recent negative readouts from Roche's (RHHBY) tiragolumab studies pressured the entire TIGIT space, but those results are likely "immature", and based on etigilimab's early activity in gynecological tumors, he expects the next driver to be a readout from Roche's study of tiragolumab in cervical cancer, Messer tells investors in a research note.

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

Over a month ago
Hot Stocks
Mereo announces portfolio prioritization plan, sees cash runway into late 2024 » 08:18
06/02/22
06/02
08:18
06/02/22
08:18
MREO

Mereo BioPharma

/

+

Mereo announced the…

Mereo announced the outcome of a review to update its capital allocation strategy, including general and administrative and other costs, and portfolio prioritization in light of current market conditions and recent industry clinical data announcements. This review was undertaken with the aim of maximizing shareholder value. Based on these initiatives, the Company now expects its current cash runway will be extended from "into" 2024 to late 2024. The portfolio, in order of development stage, is as follows: Setrusumab for Osteogenesis Imperfecta: As planned, Mereo will target its investment toward the activities required in support of the EU and UK territories and the ongoing collaboration with Ultragenyx Pharmaceutical, Inc. The Phase 2/3 in 5-25 year olds has been initiated by Ultragenyx and an update on the Phase 2 is expected before the end of 2022. Alvelestat for Alpha-1-Anti-Trypsin Deficiency: Mereo recently announced positive top-line data from the Phase 2 study of alvelestat in AATD. The Company intends to complete further analysis of the Phase 2 data during 2H 2022 and will evaluate further options for the program once it has completed an end-of-Phase 2 meeting with the FDA and an EMA scientific advisory meeting. As previously planned, no additional clinical development expense will be incurred for this program from the current cash resources. Etigilimab in Oncology: Mereo intends to complete enrollment in the Phase 1b part of the previously planned Phase 1b/2 study in Q3 2022. The Company will then evaluate further options based on the Phase 1b data and external factors, including clinical data from other anti-TIGIT programs. Mereo will continue to explore a range of additional financing options for its programs, including partnerships, which may include retention of certain rights and/or territories, as well as non-dilutive financing. "We conducted this strategic review over the last few months in light of current market conditions and emerging external clinical data, to focus the Company's resources on our lead programs," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "As a result of our updated capital allocation plan, our current cash balance of $111.4 million will now support our operating runway into late 2024. We believe this puts Mereo in a stronger position to maximize shareholder value and deliver on multiple milestones over the next two years as we focus on our mission of developing transformative therapies."

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

Hot Stocks
Mereo BioPharma to present data update for Phase 1b/2 ACTIVATE study » 08:16
06/02/22
06/02
08:16
06/02/22
08:16
MREO

Mereo BioPharma

/

+

Mereo BioPharma Group…

Mereo BioPharma Group announced updated clinical data from its open-label Phase 1b/2 Study of Etigilimab and Nivolumab in subjects with Select Locally Advanced or Metastatic Solid Tumors. The data will be presented in a poster session at the 2022 American Society of Clinical Oncology Annual Meeting on June 5, 2022. The Company also provided an update on its capital allocation and portfolio prioritization plan. The multicenter ACTIVATE study is designed to evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics of etigilimab, in combination with nivolumab, with dosing every two weeks. As of the cut off date of April 20, 2022, there were 38 efficacy-evaluable subjects with a minimum of 1 staging scan or documented clinical progression. Treatment of etigilimab in combination with nivolumab has shown preliminary efficacy across multiple tumor types with 2 complete responses, 4 partial responses, and 10 stable disease for an overall response rate of 15.8% and disease control rate of 42.1% in heavily pre-treated, CPI-naive subjects. Additionally, 7 subjects with clinical benefit remained on study treatment for greater than or equal to 18 weeks. Clinical benefit was noted in tumor types not typically responsive to immune checkpoint inhibitor monotherapy. The combination of etigilimab and nivolumab has been safe and well tolerated, with no new treatment-related SAEs or safety signals observed to-date. "We are very pleased with these updated results from the ACTIVATE study and look forward to sharing our findings at ASCO," said Dr. Suba Krishnan, Senior Vice President, Clinical Development of Mereo. "We are encouraged by the results reported as of the cut-off date, especially the early efficacy noted in cervical cancer, where we have seen two complete responses and two cases of stable disease among five subjects, and in uveal melanoma subjects in the rare tumor cohort, where we saw one partial response and two stable disease with over 20 weeks on study treatment. While these early data are encouraging for our differentiated clinical strategy, we will continue to monitor emerging clinical data on other anti-TIGIT therapeutics as we determine the most appropriate path forward for etigilimab."

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

Conference/Events
Mereo BioPharma management to meet virtually with BTIG » 04:55
06/01/22
06/01
04:55
06/01/22
04:55
MREO

Mereo BioPharma

/

+

Virtual Meetings to be…

Virtual Meetings to be held on May 31-June 1 hosted by BTIG.

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

Conference/Events
Mereo BioPharma management to meet virtually with BTIG » 04:55
05/31/22
05/31
04:55
05/31/22
04:55
MREO

Mereo BioPharma

/

+

Virtual Meetings to be…

Virtual Meetings to be held on May 31-June 1 hosted by BTIG.

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

Hot Stocks
Mereo BioPharma to present updated Phase 1b/2 data on Etigilimab and Nivolumab » 18:57
05/26/22
05/26
18:57
05/26/22
18:57
MREO

Mereo BioPharma

/

+

Mereo BioPharma announced…

Mereo BioPharma announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors at the 2022 ASCO Annual Meeting June 3 - 7. At the time of the February 10 abstract deadline, of the 27 efficacy-evaluable subjects with minimum of 1 staging scan or radiological/clinical progression, 12 subjects had a clinical benefit with 1 CR, 2 PRs and 9 SDs and 15 subjects had radiological/clinical progression, with an overall response rate of 11% and disease control rate of 44%. The combination of etigilimab and nivolumab has been safe and well tolerated, with no new safety signals observed to-date.

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

Conference/Events
Mereo BioPharma management to meet virtually with BTIG » 13:55
05/24/22
05/24
13:55
05/24/22
13:55
MREO

Mereo BioPharma

/

+

Virtual Meetings to be…

Virtual Meetings to be held on May 31-June 1 hosted by BTIG.

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

Hot Stocks
Mereo BioPharma announces appointment of Mullick to board of directors » 08:05
05/17/22
05/17
08:05
05/17/22
08:05
MREO

Mereo BioPharma

/

+

, KYKOF

Kyowa Kirin

$21.22 /

+ (+0.00%)

Mereo BioPharma (MREO)…

Mereo BioPharma (MREO) announced the appointment of Dr. Abdul Mullick to the Company's Board of Directors, effective immediately. Dr. Mullick currently serves as President & Chief Executive Officer of Kyowa Kirin International, a subsidiary of Kyowa Kirin (KYKOF) the Japan-based global specialty pharmaceutical company.

ShowHide Related Items >><<
MREO Mereo BioPharma
/

+

KYKOF Kyowa Kirin
$21.22 /

+ (+0.00%)

MREO Mereo BioPharma
/

+

KYKOF Kyowa Kirin
$21.22 /

+ (+0.00%)

02/17/22 SMBC Nikko
Kyowa Kirin upgraded to Outperform from Neutral at SMBC Nikko
07/14/21 Goldman Sachs
Kyowa Kirin downgraded to Neutral from Buy at Goldman Sachs

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.